PBAC Submission support for listing of Dupilumab (Dupixent®) on the PBS - 20 January 2022
Allergy & Anaphylaxis Australia lodged a submission with Pharmaceutical Benefits Advisory Committee (PBAC) supporting the Pharmaceutical Benefits Scheme (PBS) listing of Dupilumab (Dupixent®) for the treatment of severe atopic
dermatitis (commonly known as eczema) in children aged 6 to 11 years.
A&AA PBAC Submission for listing of Dupilumab (Dupixent®) - 20 January 2022105.85 KB